North Shore University Hospital has started using a new rapid blood test that can help emergency department physicians ...

For much of his 11 years as governor, Greg Abbott has lived by the same motto in election years when his name was on the ballot. In Texas, all candidates for statewide office are on their own. Each ...

Abbott (NYSE:ABT) today announced positive early results from a study evaluating its investigational Amulet 360 left atrial appendage (LAA) occluder. Amulet 360, a next-generation implant, was ...

Abbott is facing a warning letter from FDA regarding its Freestyle Libre family of continuous glucose monitoring (CGM) devices for use in diabetes management. The agency said it received responses ...

Feb. 4 (UPI) --Officials for Abbott Diabetes Care have recalled some of the company's FreeStyle Libre 3 and FreeStyle Libre 3 Plus continuous glucose monitor sensors for people with diabetes. The Food ...

The sensor for the next-generation FreeStyle Libre 3 CGM is the same size as two U.S. pennies stacked together. [Image courtesy of Abbott] Abbott (NYSE:ABT) is facing an FDA warning letter alleging ...

Abbott received a warning letter from the Food and Drug Administration related to its FreeStyle Libre continuous glucose monitors. The warning letter, dated Jan. 23 and posted to the FDA’s website on ...

Texas Gov. Greg Abbott called on the state's attorney general to strip the Council on American-Islamic Relations of its non-profit status Thursday. Abbott made the request in a letter to Attorney ...

Texas Gov. Greg Abbott on Monday expanded a list of prohibited technologies for state employees and devices, adding a range of Chinese electronics manufacturers, artificial intelligence companies and ...

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

ABT stock: Abbott fell 8% after Q4 revenue missed forecasts at $11.5B with nutrition sales down 8.9% as price increases hurt demand and costs stayed high. Abbott Laboratories shares fell 8% after Q4 ...